The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

Hallym University

Status: Unknown

Conditions: Central Serous Chorioretinopathy

Treatments: Procedure: intravitreal injection with anterior paracentesis

Study type: Interventional

Funder types: Other

Identifiers

NCT00864773

2009-3-16

Details and patient eligibility

About

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Enrollment: 10 estimated patients

Sex: All

Ages: 30 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of central serous chorioretinopathy
• Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography
• Presence of focal leaks at the level of the RPE on fluorescein angiography

Exclusion criteria

• Known side effects of systemic bevacizumab administration
• Have a significant cardiovascular or thromboembolic history or were pregnant

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind